Clinical Trial Update: Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of pegylated interferon-alpha-2b added to dasatinib in newly diagnosed chronic phase myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)
• Pegylated Interferon Alpha-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: Norwegian University of Science and Technology | Conditions: Leukemia, Myeloid, Chronic-Phase | Phase 2 | Status: COMPLETED